newsfilter
← Latest News
Business Wire·

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

- Collaboration with Amgen to explore the clinical potential of Zai Lab's DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen's IMDELLTRA® - Amgen to sponsor and lead global Phase 1b study; Zai